Ignite Creation Date:
2024-05-06 @ 4:15 PM
Last Modification Date:
2024-10-26 @ 2:06 PM
Study NCT ID:
NCT04923152
Status:
COMPLETED
Last Update Posted:
2021-06-11
First Post:
2021-06-06
Brief Title:
Effective Dose of Statin Post PCI
Sponsor:
Shiraz University of Medical Sciences
Organization:
Shiraz University of Medical Sciences
Study Overview
Official Title:
Effects of High- or Moderate-Dose Statin on 1-Year Major Adverse Cardiovascular Events MACE Post Percutaneous Coronary Interventions
Status:
COMPLETED
Status Verified Date:
2021-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
In this study post coronary stenting patients were enrolled to receive moderate dose versus high dose statin for 1 year and the result of major adverse cardiovascular events were recorded
Detailed Description:
In this randomized double-blind clinical trial the study population was all patients with a recent history of PCI who referred to the professor kojuri cardiovascular clinic for the first post-procedure visit In the first visit patients were randomly divided into two groups Both groups were treated with Rosuvastatin 40 mg as high potency statin for one month after PCI In the first group after one month the statin level changed to Rosuvastatin 5 mg daily moderate intensity In the second group 40 mg of Rosuvastatin was continued for one year Then the participants were evaluated in terms of MACEs including any hospitalization due to acute coronary syndrome as well as history of stroke and myocardial Infarction subsequent unplanned revascularization and cardiac death The HS-CRP also checked between two groups
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None